A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
CorrectSequence Therapeutics Co., Ltd
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 20
- sponsor
- CorrectSequence Therapeutics Co., Ltd
- conditions
- β-thalassemia Major
- interventions
- GENETIC: CS-101 injection
- start date
- 2026-04-05
- start date type
- ESTIMATED
- primary completion date
- 2028-01-31
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07489196
- Published
- Mar 24, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07489196
- Categories
- β-thalassemia Major
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials